TREACE MEDICAL CONCEPTS, INC. (TMCI) research
TREACE MEDICAL CONCEPTS, INC.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $4.39
- As of
TREACE MEDICAL CONCEPTS, INC. (TMCI): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-07.
As of . Source: SEC EDGAR filings for TMCI. Method and limitations.
Share the TMCI intelligence card
See the full TMCI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TMCI on one page. Preview it with sample data, then open it live with a free account.
Preview the TMCI dossierActive signals for TMCI
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 91% of TMCI (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 82% of TMCI (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +606% to TMCI (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 21.1%, EPS $-0.24 vs $-0.304 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 9.0% - EPS $-0.26 vs $-0.2856 estimate
FREE, NO ACCOUNT
Every signal on TMCI, as it fires
You are seeing 5 of 6 signals recorded on TMCI since 2026-05-26.
The five above landed across 3 days. The other 1 were recorded on those same days. 3 of the 6 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TMCI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 89455T109 · 2026Q2 | $2.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 89455T109 · 2026Q2 | $2.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 89455T109 · 2026Q2 | $2.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 89455T109 · 2026Q2 | $192K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TMCI
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TMCI against its peers
TMCI's operating margin of -25.5% ranks in the 48th percentile of 21 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | TMCI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 213M USD | 85.2M USD | 80 | 21 |
| Gross margin | 79.8% | 56.0% | 84 | 21 |
| Operating margin | -25.5% | -21.1% | 48 | 21 |
| Net margin | -27.7% | -28.5% | 52 | 21 |
| Return on equity | -67.6% | -34.0% | 36 | 20 |
| P / E | n/a | 25.8x | n/a | 6 |
Peers (22): LAB, TLSI, CATX, INFU, CV, QSI, VMD, CLPT, ELMD, RCEL, OFIX, STIM, NPCE, QTRX, EBRCZ, TCMD, SENS, MASS, DCTH, OWLT, KIDS, SSII. Left out: MOBI (no annual filing), PROF (no annual filing), BWAY (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TMCI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TMCI signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TMCIand get the insider, 13F, options, and confluence read in one view.